Latest News

The indication is for adults with PTEN-deficient metastatic androgen pathway modulation-naïve or modulation-sensitive prostate cancer.

What began as a modest survey has grown into one of the most trusted barometers of frontline pharmaceutical expertise in the country.

EHA 2026 data show Sonrotoclax plus zanubrutinib drives rapid, durable uMRD in frontline CLL, even TP53/del17p.

A post hoc analysis of ATTAIN-1 and ATTAIN-2 presented at ADA 2026 found orforglipron (Foundayo) significantly reduced body weight and waist circumference in women regardless of menopausal stage.

Real‑world study finds grade 1 CRS during CD20 bispecific therapy for follicular lymphoma is often safe at home, reducing hospital use.

The landscape of cardiovascular prevention is shifting from a focus on surrogate biomarkers to a more granular, image-based assessment of actual disease burden.

Data presented at EHA 2026 continue to support venetoclax plus obinutuzumab as a first-line treatment for patients with chronic lymphocytic leukemia (CLL).

The indication is for adjuvant treatment of adults with high-risk clear cell renal cell carcinoma (RCC) following nephrectomy, based on LITESPARK-022 showing a significant improvement in disease-free survival.

Student pharmacists boost dermatology literacy in underserved communities, improving sunscreen habits, skin cancer warning recognition, and practical skin health self-care.

Mayo Clinic tackles medication shortages with batching and fair overtime, keeping oncology acetaminophen available in a Pharmacy Times peer review.

MRD monitoring detects microscopic disease levels to guide treatment decisions, providing actionable insights for pharmacists.

New 2026 lipid guidelines push earlier screening, PREVENT risk scoring, and tougher LDL/ApoB targets with expanded nonstatin options.

A reflection from HOPA 2026 explores medical misinformation and how oncology pharmacists can strengthen trust and guide evidence-based patient care.

frontMIND phase 3 trial data show tafasitamab plus lenalidomide with R-CHOP boosts PFS and has manageable safety in high-risk newly diagnosed DLBCL.

Skin Cancer Awareness Month in May spotlights oncology pharmacists driving prevention, innovative care, and supply-chain resilience built on patient trust.

Although polypharmacy is common in older adults and may increase the risk of adverse events and drug-drug interactions, statin therapy may continue to provide benefit in patients older than 75 years.

Time to next treatment (TTNT) is an emerging real-world end point in CAR T-cell therapy that reflects treatment durability, clinical outcomes, and health care system factors beyond traditional efficacy measures.

The misinformation is rampant, the adverse effect expectations are wildly off, and the patient psychology is complex.

Temperature differences between exhaled air and ambient environments significantly affect how respiratory aerosols disperse.

Chai Discovery’s collaboration with Eli Lilly highlights the growing role of AI in biologics discovery, leveraging generative AI models to accelerate design and optimization of novel therapeutic proteins and antibodies.

Although evidence supports safety of apixaban and rivaroxaban relative to warfarin, researchers have not directly compared their bleeding risk until last year.